Press Release

The final histopathology and lab report supplements previous positive Company findings. The results of the study will support the Company’s IDE submission to the FDA to commence its human clinical study. BRAINTREE, Mass. , Dec. 07, 2023 (GLOBE NEWSWIRE) -- Microbot Medical Inc.

The former Senior Medical Director for the Peripheral Interventions Division at Boston Scientific Corporation joins the Company as it transitions to the clinical and regulatory phase. BRAINTREE, Mass. , Nov. 21, 2023 (GLOBE NEWSWIRE) -- Microbot Medical Inc.

The V&V process is an additional key milestone toward regulatory submission and is required to continue the regulatory process with the FDA BRAINTREE, Mass. , Nov. 13, 2023 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), developer of the innovative LIBERTY ® Robotic Surgical System, today

BRAINTREE, Mass. , Nov. 08, 2023 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), the developer of the LIBERTY ® Robotic Surgical System, the first single-use endovascular robotic system, today announced it had been granted a registered trademark from the US Patent and Trademark Office .

Follow up visual examination three days after the procedures using the LIBERTY Robotic Surgical System, confirms 100% success rate in reaching the targets with no adverse events BRAINTREE, Mass. , Oct. 31, 2023 (GLOBE NEWSWIRE) -- Microbot Medical Inc.

The Company’s designated   N otified B ody confirmed dates for conducting audits for ISO 13485 certification to ensure Microbot complies with the QMS requirements of the EU MDR The Company expects that t he full   CE Mark a pproval process of obtaining clearance of sales in the European Union for

BRAINTREE, Mass. , Oct. 19, 2023 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), developer of the innovative LIBERTY ® Robotic Surgical System, today announces that the United States District Court for the Southern District of New York , approved Microbot’s motion for summary judgment and

A total of 48 animal targets were reached with 100% usability and technical success and no visual acute intra-operative adverse events or complications This pivotal study , together with the verification and validation stud ies , is expected to serve as the basis for the IDE submission to the FDA

The engagement is an additional step in the Company's path towards marketing clearance with the FDA BRAINTREE, Mass. , Sept. 27, 2023 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), the developer of the LIBERTY ® Robotic Surgical System, the first single-use endovascular robotic system,